- Home
- SPRO
as 11-22-2024 9:38am EST
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 62.7M | IPO Year: | 2017 |
| Target Price: | $5.00 | AVG Volume (30 days): | 470.6K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.01 - $1.89 | Next Earning Date: | 11-14-2024 |
| Revenue: | $106,455,000 | Revenue Growth: | 37.01% |
| Revenue Growth (this year): | -70.46% | Revenue Growth (next year): | -41.22% |
Stock Insider Trading Activity of Spero Therapeutics Inc. (SPRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rajavelu Esther | SPRO | CFO & CBO | Nov 7 '24 | Sell | $1.31 | 40,596 | $53,008.31 | 396,515 | |
| Keutzer Timothy | SPRO | Chief Operating Officer | Aug 27 '24 | Sell | $1.35 | 2,213 | $2,987.55 | 531,837 | |
| Mahadevia Ankit | SPRO | Director | Aug 27 '24 | Sell | $1.35 | 5,912 | $7,981.20 | 759,085 | |
| Shukla Sath | SPRO | CEO & President | Aug 27 '24 | Sell | $1.35 | 2,757 | $3,721.95 | 1,140,809 |
Latest Spero Therapeutics Inc. News
SPRO Breaking Stock News: Dive into SPRO Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
Zacks
4 days ago
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
Zacks
5 days ago
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
Zacks
6 days ago
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
Clinical Trials Arena
6 days ago
TenNor’s Phase III antibiotic trial meets all primary endpoints
Zacks
7 days ago
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
Simply Wall St.
8 days ago
Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
10 days ago
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
Compare SPRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRO Spero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.